Pregabalin EQL Pharma belongs to a drug group used to treat epilepsy, neuropathic pain and generalized anxiety disorder in adults.

The market for pregabalin in Sweden is large with an annual value of approximately 225 million SEK and is today made up of, not counting parallell traders, the originator Lyrica© from Pfizer as well as generics from an additional six companies.

Pregabalin EQL Pharma is planned for launch during the second quarter 2019.